The TGF-β superfamily as potential therapeutic targets in pancreatic cancer

Front Oncol. 2024 Mar 4:14:1362247. doi: 10.3389/fonc.2024.1362247. eCollection 2024.

Abstract

The transforming growth factor (TGF)-β superfamily has important physiologic roles and is dysregulated in many pathologic processes, including pancreatic cancer. Pancreatic cancer is one of the most lethal cancer diagnoses, and current therapies are largely ineffective due to tumor resistance and late-stage diagnosis with poor prognosis. Recent efforts are focused on the potential of immunotherapies in improving therapeutic results for patients with pancreatic cancer, among which TGF-β has been identified as a promising target. This review focuses on the role of TGF-β in the diseased pancreas and pancreatic cancer. It also aims to summarize the current status of therapies targeting the TGF-β superfamily and postulate potential future directions in targeting the TGF-β signaling pathways.

Keywords: TGF-β; acute pancreatitis; chronic pancreatitis; pancreatic ductal adenocarcinoma; pancreatic stellate cells.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was partially supported by the NIH R21 AA027014 and Jack H Mayfield M.D. Distinguished Professorship in Surgery (TK), Dean’s fund for Summer Research Program at UTHealth MMS (RT). JB-L is supported by NIH R01 CA277161.